

Attorney Docket No.: **ISPH-0519**
Inventors: **Monia et al.**
Serial No.: **09/715,983**
Filing Date: **November 20, 2000**
Page 2

In the Claims:

Please cancel claim 3.

Please amend claim 1 as follows:

1. (amended) An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human PI3K p85 (SEQ ID NO: 1), wherein said antisense compound specifically hybridizes with and inhibits the expression of human PI3K p85.

REMARKS

Claims 1-63 are pending in this application. Claim 3 has been canceled. Claim 1 has been amended. No new matter has been added by this amendment. Reconsideration is respectfully requested in view of these amendments and the following remarks.

The claims of the present application have been subjected to a Restriction Requirement under 35 U.S.C. §121 and 37 C.F.R. §1.141 by the Examiner in this case. The Examiner suggests that claim 3 specifically claims multiple individual antisense sequences each of which are deemed to constitute individual inventions. The Examiner further suggests that the sequences are distinct as each SEQ ID NO. is a unique nucleotide sequence, and each sequence targets different and specific regions of PI3K p85, modifying expression of